Managing novel therapies and concomitant medications in chronic lymphocytic leukemia: key challenges

Managing novel therapies and concomitant medications in chronic lymphocytic leukemia: key challenges

The treatment of chronic lymphocytic leukemia (CLL) consists of the continuous use of Bruton tyrosine kinase inhibitors (BTKis) such as ibrutinib, acalabrutinib, zanubrutinib and pirtobrutinib, or Bcl-2 inhibitors, such as venetoclax. Overall survival (OS) and progression-free survival (PFS) of CLL...

Full description

Saved in:
Bibliographic Details
Main Authors: Sofija Kozarac, Jelena Ivanovic, Marko Mitrovic, Kristina Tomic Vujovic, Isidora Arsenovic, Nada Suvajdzic-Vukovic, Andrija Bogdanovic, Ana Vidovic, Milena Todorovic-Balint, Jelena Bila, Mirjana Mitrovic, Danijela Lekovic, Irena Djunic, Marijana Virijevic, Aleksandar Trivic, Jelena Micic, Darko Antic
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Pharmacology
Subjects:
chronic lymphocytic leukemia
Bruton tyrosine kinase inhibitors
venetoclax
drug-drug interactions
comorbidities
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1517972/full
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items